TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04927260
Drug: Patient treated by Avapritinib in real life
Normalized name: Avapritinib
DrugBank: Avapritinib (DB15233)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The patients included are treated with Avapritinib as part of their care. There is no change in treatment associated with this study.~Patients must regularly complete various questionnaires: FACT-G, FACT-COG, and a neuropsychiatrist or a trained physician will give them the MoCA.
Study: NCT04530994
Drug: maralixibat
Normalized name: Maralixibat
DrugBank: Maralixibat (DB16226)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maralixibat is an Apical Sodium-dependent Bile acid Transporter (ASBT) inhibitor
Study: NCT05245760
Drug: Intravenous Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 200mg, every three weeks for up to 51 weeks
Study: NCT05561660
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants randomized into this group will take aspirin 200mg qd for 6 months.
Study: NCT05009771
Drug: Dinalbuphine sebacate
Normalized name: Dinalbuphine sebacate
DrugBank: Dinalbuphine sebacate (DB15341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinalbuphine sebacate is a prodrug of nalbuphine. With oil-based formulation, the active ingredient releases slowly and the effect lasts longer than nalbuphine. After delivery, a single 150 mg dose of dinalbuphine sebacate is administered intramuscularly.
Study: NCT05221021
Drug: Vaginal estrogen
Normalized name: estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.01% estradiol cream 1/2 gram applied vaginally once nightly for two weeks then three times per week with once daily placebo oral pill
Study: NCT04394533
Drug: Prilocaine (Hyperbaric 2%)
Normalized name: Prilocaine
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 ml hyperbaric prilocaine
Study: NCT05221021
Drug: Mirabegron 50 MG [Myrbetriq]
Normalized name: mirabegron 50 MG [Myrbetriq]
DrugBank: Mirabegron (DB08893)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 50mg oral Mirabegron once daily
Study: NCT04394533
Drug: Bupivacaine (Hyperbaric 0.5%)
Normalized name: bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 ml hyperbaric bupivacaine
Study: NCT05468632
Drug: Semaglutide
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants who initiated once weekly (OW) semaglutide in routine clinical practice in were enrolled in the study. The participants were treated according to current clinical practice, applicable local labels, and standard of care as per physicians' discretion.
Study: NCT06281860
Drug: Cisplatine Teva®
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PITHAC: Cisplatin (Cisplatine Teva®) at a dose between 7.5 and 70 mg/m2 of body surface at a temperature of 39±1°C
Study: NCT06006793
Drug: SY-5933
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: KRAS p.G12C inhibitor
Study: NCT00002278
Drug: Diclazuril
Normalized name: Diclazuril
DrugBank: Diclazuril (DB11398)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04745130
Drug: Sintilimab，regofinib，cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: KRAS BRAF wild type Sintilimab 200mg d1q3w+ regofinib 80mg d1-21 q4w with cetuximab 500mg/m2 q2w
Study: NCT04745130
Drug: KRAS BRAF mutant Sintilimab + regafinil
Normalized name: Streptococcus mutans
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KRAS BRAF mutant Sintilimab 200mg D1 Q3W + regafinil 80mg D1-21 Q4W
Study: NCT04943029
Drug: Carrelizumab
Normalized name: CERTOLIZUMAB
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Camrelizumab: 200mg, IV, day 1 of each 21-day cycle, neoadjuvant therapy : 3 cycles; Adjuvant therapy: 16cycles.
Study: NCT04943029
Drug: Pemetrexed (Nonsquamous NSCLC) or Nab-paclitaxel(Squamous NSCLC)
Normalized name: Paclitaxel
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel: 260mg/m\^2, IV, day 1 of each 21-day cycle, 3 cycles; Pemetrexed: 500 mg/m\^2, IV, day 1 of each 21-day cycle, 3 cycles.
Study: NCT04943029
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 i.v. on day 1 of each 21-day cycle for 3 cycles.
Study: NCT05357235
Drug: PEG-IFN
Normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEG-IFN 180 or 135 micrograms, subcutaneously injected once a week, with a personalized treatment course of 24 weeks
Study: NCT04756505
Drug: Bintrafusp Alfa
Normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT06268665
Drug: Tart Cherry Juice
DrugBank: Cherry (DB10518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT06561867
Drug: Ticagrelor 90 MG
Normalized name: ticagrelor 90 MG
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efficacy and safety of a 180 mg loading dose of ticagrelor administered within 24 hours of first-ever ischemic stroke followed by 90 mg twice daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects
Study: NCT06561867
Drug: Cilostazol 100 MG
Normalized name: cilostazol 100 MG
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efficacy and safety of 200 mg clopidogrel followed by 100 mg twice daily for 3 months will be assessed through NIHSS, mRS, duration of hospital stay, new ischemic stroke, and possible adverse effects.
Study: NCT05348057
Drug: Ivabradine
Normalized name: Ivabradine
DrugBank: Ivabradine (DB09083)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The starting dose is 5 mg twice a day. Adjust the dose according to the actual situation
Study: NCT05677555
Drug: Colchicine 0.5 MG
Normalized name: colchicine 0.5 MG
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A total of 25 subjects will be randomized to treatment with COLCHICINE 0.5 mg, three times a week (at the end of each hemodialysis session) over the 3 month study period.
Study: NCT04234906
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine: 1 mcg/kg administered over 20 min peri-intubation period, followed by a 0.5 mcg/kg/h infusion for 72 h postoperatively or ready for extubation prior to 72 hour time period
Study: NCT04234906
Drug: Magnesium Sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium Sulfate (50 mg/kg) bolus administered at the time of Aortic Cross Clamp Release, with continued administration for 72 hours postoperatively at a dose of 30 mg/kg/day
Study: NCT04234906
Drug: Amiodarone
Normalized name: Amiodarone
DrugBank: Amiodarone (DB01118)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: I V Amiodarone 2.5 mg/kg administered over 30 minutes Second 2.5 mg/kg dose if needed over 30 minutes Continuous Intravenous Infusion 10-15 mg/kg/24 hours
Study: NCT04234906
Drug: Procainamide
Normalized name: Procainamide
DrugBank: Procainamide (DB01035)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV Procainamide 10-15 mg/kg administered over 45 minutes Continuous Intravenous Infusion 20-50 mcg/kg/min
Study: NCT06225921
Drug: Adebrelimab
Normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adebrelimab will be given at a dose of 20 mg per kilogram of body weight every three weeks on day 23 of a planned 28-day cycle, and two doses before surgery.
Study: NCT06225921
Drug: Dalpiciclib 100mg
Normalized name: Dalpiciclib
DrugBank: Dalpiciclib (DB17456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalpiciclib will be given at a dose of 100 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for two cycles.
Study: NCT06225921
Drug: Dalpiciclib 150mg
Normalized name: Dalpiciclib
DrugBank: Dalpiciclib (DB17456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalpiciclib will be given at a dose of 150 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for two cycles.
Study: NCT05305248
Drug: Remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: After spinal anesthesia, 5 mg of remimazolam is injected by intravenous route for 1 minute to induce sedation. To maintain sedation, remimazolam is continuously infused at a rate within the range of 0.1 mg/kg/h to 1 mg/kg/h.
Study: NCT05305248
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: After performing spinal anesthesia, dexmedetomidine is injected at a loading dose of 1 mcg/kg for 10 minutes to induce sedation. Thereafter, to maintain sedation, Dexmedetomidine is continuously infused at a rate within the range of 0.2 to 0.7 mcg/kg/h.
Study: NCT05463770
Drug: SEP-363856
Normalized name: SEP-363856
DrugBank: SEP-363856 (DB15665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SEP-363856, 12.5 mg, 25 mg, and 50 mg tablets. The dose taken at the same time each day, in the evening and in the morning. Multiple tablets may be required to achieve a single dose.
Study: NCT00283764
Drug: Xalatan
Normalized name: Xalatan
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT05551273
Drug: Selgantolimod
Normalized name: Selgantolimod
DrugBank: Selgantolimod (DB16324)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg tablet
Study: NCT05560646
Drug: OG-6219
Normalized name: IODINE 4000 mg in 1 L TOPICAL SOLUTION, CONCENTRATE [Multi Dose OG]
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: OG-6219 Dose 1, Dose 2, Dose 3 BID: Participants will receive (orally) OG-6219 tablets during treatment cycles.
Study: NCT06560086
Drug: Ketoconazole
Normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A fetal developmental stage is precisely determined. Then, fetal tissues are extracted for in vitro cultivation. Intact aborted fetal testicular tissues are cultured in a medium containing 10-6 mol/L ketoconazole, which is the injectable solution powder. Ketoconazole is administered starting on the first day and then every other day, for a total of 7 times over the 14-day in vitro culture period.
Study: NCT06560086
Drug: Luteinizing Hormone
Normalized name: LUTEINIZING HORMONE
DrugBank: Luteinizing hormone (DB14741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A fetal developmental stage is precisely determined. Then, fetal tissues are extracted for in vitro cultivation. Intact aborted fetal testicular tissues are cultured in a medium containing 1 IU/mL luteinizing hormone, which is the injectable solution powder. Luteinizing hormone is administered starting on the first day and then every other day, for a total of 7 times over the 14-day in vitro culture period.
Study: NCT04314856
Drug: 18F-FTC-146
Normalized name: (-)-FTC
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 18F-FTC-146 is a PET radiopharmaceutical that can be used to determine sigma-1 receptor density.
Study: NCT05026398
Drug: Fenfluramine
Normalized name: fenfluramine
DrugBank: Fenfluramine (DB00574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenfluramine (30mg daily) will be dispensed in a cherry flavoured aqueous solution. Fenfluramine is both a serotonin releasing agent and sigma-1 receptor agonist. Fenfluramine is FDA approved for the treatment of Dravet syndrome, a rare form of epilepsy.
Study: NCT05374538
Drug: sotorasib
Normalized name: SOTORASIB
DrugBank: Sotorasib (DB15569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sotorasib tablets for oral administration
Study: NCT05407584
Drug: Orevogomab+Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: paclitaxel (80 mg / m2 IV over three hours in one day) to be repeated till progression or unacceptable toxicity every four weeks on day 1, 8, 15~Investigational agent (Oregovomab): 2 mg diluted in 50 mL saline for injection administered IV following paclitaxel over approximately 20 (acceptable range 15-30) minutes for a total of 5 scheduled injections, one each at Cycle 1, Cycle 2, Cycle 3, Cycle 5, and Cycle 7
Study: NCT04990466
Drug: Active Comparator
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of a currently-approved vaccine for COVID-19
Study: NCT06078969
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: For the experimental group, the patient will be administrated oral prednisone (0.5mg/kg/day, first 5 days per month, 6 months)
Study: NCT06437678
Drug: Liposomal Irinotecan Hydrochloride
Normalized name: irinotecan hydrochloride liposome
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Liposomal Irinotecan Hydrochloride Injection (Ⅱ) 56.5mg/m2 every 2 weeks
Study: NCT04870606
Drug: Proxalutamide (GT0918)
Normalized name: Proxalutamide
DrugBank: Proxalutamide (DB16065)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proxalutamide (GT0918)+Standard of care determined by PI and local regulatory
Study: NCT05726344
Drug: Lactulose
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4 tablets of Bisacodyl (5 mg) + 250 mL (162.5g lactulose) of lactulose + 600 mL of water + 2 L of water
Study: NCT05726344
Drug: Polyethylene Glycol 3350
Normalized name: Polyethylene Glycol 3350
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 tablets of Bisacodyl (5 mg) + 3 bottles Polyethylene Glycol 3350 (Polyethylene glycol 3350 60 g; sodium chloride 1.46 g; potassium chloride 745 mg; Sodium bicarbonate 1.68 g; anhydrous sodium sulfate 5.68 g; pineapple flavoring 483 mg) + 3 L of water
Study: NCT05988671
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraperitoneal route
Study: NCT05988671
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraperitoneal route
Study: NCT05988671
Drug: Combination of dexamethasone + dexmedetomidine
Normalized name: dexamethasone, combinations
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraperitoneal route
Study: NCT05965284
Drug: Telitacicept
Normalized name: Telitacicept
DrugBank: Telitacicept (DB18312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will be treated with Telitacicept (Taiai the commercial name) 160 mg every week subcutaneously for 12 months
Study: NCT05098990
Drug: Platinum-based doublet chemotherapy
Normalized name: platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platinum-based doublet chemotherapy as first line therapy has been shown to be efficacious against non-small cell lung cancer.
Study: NCT05667129
Drug: XEN-101
Normalized name: XEN-2174
DrugBank: XEN-2174 (DB05012)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule formulation
Study: NCT05315557
Drug: Terlipressin
Normalized name: Terlipressin
DrugBank: Terlipressin (DB02638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1mg/24 hour and titrate according to MAP
Study: NCT05315557
Drug: vasopressin
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.03 U/hour and titrate according to MAP
Study: NCT04455139
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravitreal or intra-arterial administration of topotecan
Study: NCT04455139
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: intravitreal or intra-arterial administration of topotecan
Study: NCT05091320
Drug: Mechanical thrombectomy
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
DrugBank: Piperonyl butoxide (DB09350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mechanical thrombectomy is interventional method and the first line management in large vessel occlusion in acute ischemic stroke
Study: NCT05602103
Drug: use of anticancer drugs in monotherapy or in combination therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cases of cancer therapy-related cardiac dysfunction associated with anticancer drugs will be identify and describe
Study: NCT05472350
Drug: Breztri Aerosphere
Normalized name: Breztri Aerosphere
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Breztri Aerosphere is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema).
Study: NCT05350917
Drug: Tislelizumab
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab: 200 mg, d1, intravenous infusion (ivgtt) administration, 21 days as a cycle.~DisitamabVedotin : 2mg/kg, d1, intravenous drip (ivgtt) administration, 21 days as a cycle.~Pyrotinib maleate tablets: 320 mg each time, Qd, orally administered within 30 minutes after breakfast, 21 days as a cycle.~Continuous administration until disease progression, death, toxicity intolerance, withdrawal of informed consent, or other reasons specified in the protocol; for patients who still benefit after comprehensive evaluation after initial disease progression, the investigator may decide whether to continue the treatment with the experimental drug .
Study: NCT05618821
Drug: Indocyanine Green Tracer
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Laparoscopic gastrectomy with lymph node dissection for remnant gastric cancer using Indocyanine Green Tracer
Study: NCT04839380
Drug: ruxolitinib cream
Normalized name: ruxolitinib Topical Cream
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ruxolitinib cream 1.5% will be applied twice daily as a thin film
Study: NCT06494189
Drug: Afatinib
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 30mg PO QD
Study: NCT04976257
Drug: Gallium Ga-labeled PSMA-11
Normalized name: Gallium Ga 68 PSMA-11
DrugBank: Gallium nitrate (DB05260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV and IA
Study: NCT06028633
Drug: pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: pembrolizumab 200mg IV on day 1 for every 3 weeks
Study: NCT06028633
Drug: lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: lenvatinib 8mg taken orally every day
Study: NCT06028633
Drug: albumin-bound paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: albumin-bound paclitaxel IV 100mg/m2 D1, 8 every 3 weeks
Study: NCT04316169
Drug: Abemaciclib
Normalized name: Abemaciclib
DrugBank: Abemaciclib (DB12001)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 150 mg b.i.d
Study: NCT04316169
Drug: Hydroxychloroquine 200 mg
Normalized name: hydroxychloroquine 200 mg oral tablet
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose level: 200 mg b.i.d.
Study: NCT04316169
Drug: Faslodex
Normalized name: Faslodex
DrugBank: Fulvestrant (DB00947)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cohort B will receive Faslodex.
Study: NCT04316169
Drug: Anastrazole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cohort A will receive anastrazole or letrozole.
Study: NCT04316169
Drug: Letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cohort A will receive anastrazole or letrozole.
Study: NCT04316169
Drug: Hydroxychloroquine 400 mg
Normalized name: hydroxychloroquine 400 mg oral tablet
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose level: 400 mg. b.i.d.
Study: NCT04316169
Drug: Hydroxychloroquine 600 mg
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose level: 600 mg b.i.d.
Study: NCT01437020
Drug: SCH708980 Anti-IL-10 monoclonal
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants in Part 1 of the study will receive varying doses (0.3 mg/kg, 1.0 mg/kg, 3.0 mg/kg, or 10.0 mg/kg) of a single IV infusion of SCH708980. Participants in Part 2 of the study will receive a single IV infusion of SCH708980 on Day 1.
Study: NCT01437020
Drug: AmBisome
Normalized name: AmBisome
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants in Part 1 of the study will receive a single IV infusion of AmBisome (10 mg/kg) 7 days after they receive SCH708980. Participants in Part 2 of the study will receive varying doses (3.75 mg/kg, 5 mg/kg, or 10 mg/kg) of a single IV infusion of AmBisome on Day 8.
Study: NCT04826770
Drug: BNT162b2
Normalized name: BNT162b2 Omicron (KP.2)
DrugBank: BNT162b2 Omicron (KP.2) (DB19415)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vaccination against COVID-19
Study: NCT04826770
Drug: AZD 1222
Normalized name: aspirin / hydrocodone bitartrate Oral Tablet [Azdone]
DrugBank: AstraZeneca COVID-19 Vaccine (DB15656)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vaccination against COVID-19
Study: NCT04826770
Drug: mRNA-1273
Normalized name: MRNA-1273 SARS-COV-2
DrugBank: Moderna COVID-19 Vaccine (DB15654)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vaccination against COVID-19
Study: NCT05858619
Drug: Dupilumab
Normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: dupilumab 600 mg injection initially and then 300 mg every other week
Study: NCT05761028
Drug: CM310
Normalized name: Immunoglobulin G4 [227-proline], anti-(human interleukin 4 receptor subunit α) (human-Mus musculus monoclonal CM310 γ4-chain), disulfide with human-Mus musculus monoclonal CM310 κ-chain, dimer
DrugBank: Stapokibart (DB18990)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CM310 Recombinant Humanized Monoclonal Antibody Injection
Study: NCT05758259
Drug: combination oral and topical vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: combination vitamin D 2000 IU 1x1 and topical 7-Dehydrocholesterol 5000 mcg 2x1
Study: NCT05758259
Drug: oral placebo and topical cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral placebo and topical 7-Dehydrocholesterol 5000 mcg 2x1